Myelodysplastic Syndromes (MDS)

Abstract Outcomes are poor in patients with higher-risk myelodysplastic syndromes (HR MDS) and frontline treatment options are limited. This phase 1b study investigated safety and efficacy of venetoclax, a selective B-cell lymphoma 2 inhibitor, at the recommended phase 2 dose…

Section snippets Background Myelodysplastic neoplasms (MDS) are a heterogenous group of hematopoietic stem cell malignancies characterized by ineffective hematopoiesis and tendency to progress to acute myeloid leukemia (AML).1 Patients (pts) are risk stratified to tailor…

Dear Editor, Secondary acute myeloid leukemia (sAML), a subset of AML, may arise from antecedent hematologic disorders (antecedent myelodysplastic syndrome or chronic myelomonocytic leukemia [A-MDS/CMML]) or complication of prior cytotoxic chemotherapy or radiation therapy…

Abstract Context.—: Standardized bone marrow reporting specifically for myelodysplastic syndromes/neoplasms (MDS) is currently lacking in the literature and much needed in practice. Objective.—: To propose a standardized approach to MDS evaluation in bone marrow specimens by (1)…